CoChat

Hepcidin agonists as therapeutic tools

Open access
Casu, Carla, Nemeth, Elizabeta, Rivella, Stefano · 2018 · Blood
Cited by 128

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Abstract

Hepcidin agonists are a new class of compounds that regulate blood iron levels, limit iron absorption, and could improve the treatment of hemochromatosis, β-thalassemia, polycythemia vera, and other disorders in which disrupted iron homeostasis causes or contributes to disease. Hepcidin agonists also have the potential to prevent severe complications of siderophilic infections in patients with iron overload or chronic liver disease. This review highlights the preclinical studies that support the development of hepcidin agonists for the treatment of these disorders.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2017-11-737411

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 38 references

Research works printed but not linked: 19

  1. Oikonomidou, 2016, New strategies to target iron metabolism for the treatment of beta thalassemia, Ann N Y Acad Sci, 1368, 162, 10.1111/nyas.13018 · DOI
  2. Rechavi, 2008, Regulation of iron absorption in hemoglobinopathies, Curr Mol Med, 8, 646, 10.2174/156652408786241401 · DOI
  3. Kim, 2015, New insights into iron regulation and erythropoiesis, Curr Opin Hematol, 22, 199, 10.1097/MOH.0000000000000132 · DOI · Paper page
  4. Wang, 2016, Hepcidin regulation in the anemia of inflammation, Curr Opin Hematol, 23, 189, 10.1097/MOH.0000000000000236 · DOI · Paper page
  5. Oikonomidou, 2017, What can we learn from ineffective erythropoiesis in thalassemia?, Blood Rev, S0268-960X(17)30131-5
  6. Gardenghi, 2007, Ineffective erythropoiesis in beta-thalassemia is characterized by increased iron absorption mediated by down-regulation of hepcidin and up-regulation of ferroportin, Blood, 109, 5027, 10.1182/blood-2006-09-048868 · DOI · Paper page
  7. Schrier, 2002, Pathophysiology of thalassemia, Curr Opin Hematol, 9, 123, 10.1097/00062752-200203000-00007 · DOI · Paper page
  8. Rivella, 2015, β-thalassemias: paradigmatic diseases for scientific discoveries and development of innovative therapies, Haematologica, 100, 418, 10.3324/haematol.2014.114827 · DOI · Paper page
  9. Melchiori, 2010, beta-Thalassemia: HiJAKing ineffective erythropoiesis and iron overload
  10. Schmidt, 2014, Modulation of hepcidin as therapy for primary and secondary iron overload disorders: preclinical models and approaches, Hematol Oncol Clin North Am, 28, 387, 10.1016/j.hoc.2013.11.004 · DOI · Paper page
  11. Bourne, 2017, Hepcidin mimetic PTG–300 for treatment of ineffective erythropoiesis and iron overload. In: Seventh Congress of the International BioIron Society (IBIS) Biennial World Meeting (BioIron 2017) May 7-11, 2017 [abstract], Am J Hematol, 92
  12. Manolova, 2017, Ferroportin inhibitors improve ineffective erythropoiesis and prevent iron loading in a beta-thalassemia disease model. In: Seventh Congress of the International BioIron Society (IBIS) Biennial World Meeting (BioIron 2017) May 7-11, 2017 [abstract], Am J Hematol, 92
  13. Guo, 2013, Reducing TMPRSS6 ameliorates hemochromatosis and β-thalassemia in mice, J Clin Invest, 123, 1531, 10.1172/JCI66969 · DOI · Paper page
  14. Casu, 2016, Combination of Tmprss6-ASO and the iron chelator deferiprone improves erythropoiesis and reduces iron overload in a mouse model of beta-thalassemia intermedia, Haematologica, 101, e8, 10.3324/haematol.2015.133348 · DOI · Paper page
  15. Pasricha, 2013, Transfusion suppresses erythropoiesis and increases hepcidin in adult patients with β-thalassemia major: a longitudinal study, Blood, 122, 124, 10.1182/blood-2012-12-471441 · DOI · Paper page
  16. Silver, 2015, The hematocrit value in polycythemia vera: caveat utilitor, Leuk Lymphoma, 56, 1540, 10.3109/10428194.2014.966243 · DOI
  17. Breda, 2014, Modulators of erythropoiesis: emerging therapies for hemoglobinopathies and disorders of red cell production, Hematol Oncol Clin North Am, 28, 375, 10.1016/j.hoc.2013.12.001 · DOI
  18. Suragani, 2014, Modified activin receptor IIB ligand trap mitigates ineffective erythropoiesis and disease complications in murine β-thalassemia, Blood, 123, 3864, 10.1182/blood-2013-06-511238 · DOI · Paper page
  19. Vifor Pharma. Vifor Pharma ferroportin inhibitor enters phase-I clinical trial. http://www.viforpharma.com/en/media/press-releases/201802/2167159. Accessed 14 February 2018.

Cited by

See all 128

Metadata

Authors
Casu, C., Nemeth, E., & Rivella, S.
Venue
Blood
Published
2018-04-19
Volume
131
Issue
16
Pages
1790-1794
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2793944650
Cited by
128
References
38
FWCI
9.73
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Hepcidin agonists as therapeutic tools. https://app.cochat.ai/papers/10.1182/blood-2017-11-737411
The paper
Casu, C., Nemeth, E., & Rivella, S. (2018). Hepcidin agonists as therapeutic tools. Blood. https://doi.org/10.1182/blood-2017-11-737411

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.